NCT04109222View on ClinicalTrials.gov

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

December 10, 2019

Study Completion Date

December 10, 2019

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Fluzone High-Dose vaccine, 2019-2020 formulation

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Trial Locations (2)

40004

Investigational Site Number 8400002, Bardstown

84121

Investigational Site Number 8400001, Salt Lake City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively | Biotech Hunter | Biotech Hunter